These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 23523664)

  • 1. GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy.
    Cozzoli A; Capogrosso RF; Sblendorio VT; Dinardo MM; Jagerschmidt C; Namour F; Camerino GM; De Luca A
    Pharmacol Res; 2013 Jun; 72():9-24. PubMed ID: 23523664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
    Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
    J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.
    De Luca A; Pierno S; Liantonio A; Cetrone M; Camerino C; Fraysse B; Mirabella M; Servidei S; Rüegg UT; Conte Camerino D
    J Pharmacol Exp Ther; 2003 Jan; 304(1):453-63. PubMed ID: 12490622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
    Cozzoli A; Rolland JF; Capogrosso RF; Sblendorio VT; Longo V; Simonetti S; Nico B; De Luca A
    Neuropathol Appl Neurobiol; 2011 Apr; 37(3):243-56. PubMed ID: 20618838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
    Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
    FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low dose formoterol administration improves muscle function in dystrophic mdx mice without increasing fatigue.
    Harcourt LJ; Schertzer JD; Ryall JG; Lynch GS
    Neuromuscul Disord; 2007 Jan; 17(1):47-55. PubMed ID: 17134898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
    Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
    Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.
    Puolakkainen T; Ma H; Kainulainen H; Pasternack A; Rantalainen T; Ritvos O; Heikinheimo K; Hulmi JJ; Kiviranta R
    BMC Musculoskelet Disord; 2017 Jan; 18(1):20. PubMed ID: 28103859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization.
    Blanqué R; Lepescheux L; Auberval M; Minet D; Merciris D; Cottereaux C; Clément-Lacroix P; Delerive P; Namour F
    BMC Musculoskelet Disord; 2014 Sep; 15():291. PubMed ID: 25185887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant.
    Burdi R; Didonna MP; Pignol B; Nico B; Mangieri D; Rolland JF; Camerino C; Zallone A; Ferro P; Andreetta F; Confalonieri P; De Luca A
    Neuromuscul Disord; 2006 Apr; 16(4):237-48. PubMed ID: 16542837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophy.
    Ponnusamy S; Sullivan RD; You D; Zafar N; He Yang C; Thiyagarajan T; Johnson DL; Barrett ML; Koehler NJ; Star M; Stephenson EJ; Bridges D; Cormier SA; Pfeffer LM; Narayanan R
    Hum Mol Genet; 2017 Jul; 26(13):2526-2540. PubMed ID: 28453658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
    Capogrosso RF; Cozzoli A; Mantuano P; Camerino GM; Massari AM; Sblendorio VT; De Bellis M; Tamma R; Giustino A; Nico B; Montagnani M; De Luca A
    Pharmacol Res; 2016 Apr; 106():101-113. PubMed ID: 26930420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
    Lowe J; Floyd KT; Rastogi N; Schultz EJ; Chadwick JA; Swager SA; Zins JG; Kadakia FK; Smart S; Gomez-Sanchez EP; Gomez-Sanchez CE; Raman SV; Janssen PM; Rafael-Fortney JA
    J Neuromuscul Dis; 2016; 3(3):395-404. PubMed ID: 27822449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
    Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
    J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy.
    Zschüntzsch J; Zhang Y; Klinker F; Makosch G; Klinge L; Malzahn D; Brinkmeier H; Liebetanz D; Schmidt J
    J Neurochem; 2016 Jan; 136(2):351-62. PubMed ID: 26230042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies.
    Sanarica F; Mantuano P; Conte E; Cozzoli A; Capogrosso RF; Giustino A; Cutrignelli A; Cappellari O; Rolland JF; De Bellis M; Denora N; Camerino GM; De Luca A
    Pharmacol Res; 2019 Jul; 145():104260. PubMed ID: 31059789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recovery of damaged skeletal muscle in mdx mice through low-intensity endurance exercise.
    Frinchi M; Macaluso F; Licciardi A; Perciavalle V; Coco M; Belluardo N; Morici G; Mudò G
    Int J Sports Med; 2014 Jan; 35(1):19-27. PubMed ID: 23868681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment.
    Lynch GS; Hinkle RT; Faulkner JA
    Exp Physiol; 2000 May; 85(3):295-9. PubMed ID: 10825417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
    Janssen PM; Murray JD; Schill KE; Rastogi N; Schultz EJ; Tran T; Raman SV; Rafael-Fortney JA
    PLoS One; 2014; 9(2):e88360. PubMed ID: 24551095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.